An artificial intelligence (AI)-enabled system combining wearable sensors with personalized coaching significantly improved glycemic outcomes and enabled medication de-escalation among adults with type 2 diabetes (T2D), according to findings published in NEJM Catalyst.

The system, known as Twin Precision Treatment, uses continuous data capture from sensors along with AI-driven feedback and coaching to guide individualized lifestyle modifications.

The findings highlight the potential of AI-enabled, sensor-based systems to transform T2D management in primary care by reducing dependence on pharmacotherapy while achieving superior glycemic outcomes. However, further studies in larger and more diverse populations are needed to confirm scalability and long-term benefits.